Anacor Pharmaceuticals Inc. (Nasdaq: ANAC) reported positive results from two
Phase 3 studies of its atopic dermatitis treatment crisaborole sending the stock price soaring $46.39 to $131.00.
Anacor Pharmaceuticals reports upbeat study results
July 13, 2015 at 05:43 AM EDT
